Leiomyomas or fibroids are the most frequently diagnosed tumors of the female genital tract, and their growth seems to be steroid-hormone dependent by a yet undetermined cellular and molecular mechanism. Sexual hormones induce the secretion of growth factor peptides and the expression of their receptors, stimulating cell proliferation. One of these factors is neurotensin, and increasing evidence suggests that it can promote growth of different cancer cells. Since there are no data on neurotensin expression in normal and tumoral uterine tissue, we have analyzed the expression of NTS and NTSR1 receptor using immunohistochemistry for protein detection, in situ hybridization to detect cells expressing NTS mRNA, and RT-PCR to detect NTSR1 transcript as well as any of the alternative splice variants recently described for this receptor. We found that NTS and NTSR1 are expressed in connective cells of normal myometrium. In leiomyomas, immunoreactivity for NTS and NTSR1 receptor is colocalized in the smooth muscle cells that are also transcribing NTS. Women receiving high doses of steroids for in vitro fertilization showed tumor growth and increased immunoreactivity for neurotensin and NTSR1 receptor. Interestingly, alternative splice variants of NTSR1 receptor were detected only in tumoral tissue. These findings suggest a role of steroid hormones inducing neurotensin expression in leiomyoma smooth muscle cells. In these cells, NTS could act autocrinally through NTSR1 receptor, promoting their proliferation.
INTRODUCTION
Uterine leiomyomas or fibroids are the most common neoplasm of the female genital tract. The incidence in the population ranges from 30% to 70% in premenopausal women and increases with age [1] . The leiomyomas are monoclonal tumors of myometrial smooth muscle cells, usually surrounded by an enriched extracellular matrix. Although these tumors are benign, several associated symptoms, such as pelvic pain, profuse menstrual bleeding, or reproductive dysfunction, can severely impair women's quality of life. Although the direct cause of the development of these tumors is unknown, the action of sexual steroid hormones is accepted as a determinant. Uterine leiomyomas are estrogen and progesterone dependent by a yet undetermined cellular and molecular mechanism [1] . They show increased estrogen-receptor gene expression and enhanced sensitivity to estrogen stimulation compared to normal myometrium [1] . Progesterone seems to favor the mitogenic activity of leiomyoma cells in culture [2] and also promotes leiomyoma cell survival through up-regulating Bcl-2 protein expression [3] . Ovarian steroids influence the secretion of growth factor peptides and the expression of their receptors [4] . One of those trophic factors is neurotensin (NTS) whose transcription is enhanced by estradiol in human breast epithelial cells [5] . Nerotensin effects are mainly mediated by the high-affinity G protein-coupled receptor NTSR1, and the downstream signaling pathways stimulated after NTS coupling include mitogen-activated protein kinases, leading to stimulated cell proliferation [6] . This effect has been observed in several normal tissues, such as small bowel, colon, pancreas, and adrenal cortex [7] . Similarly, several lines of evidence suggest that NTS plays a role in the regulation of tumoral cell growth: NTS receptor binding activity and NTSR1 mRNA are highly overexpressed by a variety of primary human cancers as compared to normal tissues [8, 9] , and human cancer cell lines express high levels of NTSR1 and exhibit growth responses to subnanomolar concentrations of NTS [10] [11] [12] . Moreover, tumor cells can secrete NTS and also express NTS receptors, suggesting that in addition to paracrine and endocrine signaling an autocrine regulation by NTS is possible [10, 13] . NTSR1 is highly overexpressed in 35% of breast cancer patients, and they also show a significantly worse prognosis compared to those with low NTSR1 expression [5] . In another endocrine tumor, NTS is expressed in approximately 25% of human colon cancers due to epigenetic mechanisms linked to NTS gene hypomethylation [14] . Recently, Gui et al. [15] suggested that higher NTSR1 expression may also be an early event in the process of colonic tumorigenesis because expression increases from healthy to adenoma (benign) then to adenocarcinoma. In the same way, the pituitary adenomas express NTS independently of the type of adenoma [16] .
Because of the lack of data on neurotensin expression in normal and tumoral uterine tissues, we set out to compare the expression of neurotensin at cellular and molecular level with its high-affinity NTSR1 receptor in myometrial and leiomyomatous tissue. In addition, we have previously described new alternative splice variants of NTSR1 receptor, which are present only in prostate cancer cell lines but not in normal prostate tissue [17] . This has led us to search for isoforms in leiomyomas and myometrial tissue. In addition, given the negative impact of fibroids on reproductive function, we include in this study leiomyomas from women who had received hormonal therapy for in vitro fertilization.
MATERIALS AND METHODS

Samples
Women patients 34-47 years of age, admitted to the Hospital Universitario de Canarias (HUC) and Hospital La Colina between 2006 and 2007, were enrolled in this study after their informed consent. Ethical approval was granted by the Committee for Clinical Research Ethics of the HUC. Intramural and/or subserous leiomyoma specimens were obtained from women who underwent myomectomy/hysterectomy.
Myomectomy was carried out according to the following medical criteria: 1) myomas compromising the uterine cavity, 2) subserous myomas, 3) intramural myomas greater than 4 cm, 4) symptomatic leiomyomas, or 5) patients with unexplained sterility. The following sample groups were analyzed: 1) 20 leiomyomas from women who underwent myomectomy without any hormonal treatment, 2) 15 leiomyomas from women who underwent myomectomy after long-cycle in vitro fertilization treatment (IVF; samples were taken after one or several cycles of complete IVF), and 3) 20 women who underwent hysterectomy without any prior treatment. The samples included leiomyomas as well as the matched myometrial.
The protocol for long-cycle IVF included gonadotropin-releasing hormone analog; gonadotroph hormones, 200-300 international units (IU) daily for 11 days of follicle-stimulating hormone or follicle-stimulating hormone þ leutinizing hormone; plus 10 000 IU of human chorionic gonadotropin. Then, 24 h after oocyte retrieval, progesterone was administered at 200 IU every 12 h for 48 h, and finally every 8 h for 18 days.
The leiomyoma and uterine wall samples were fixed in 10% buffered formalin, embedded in paraffin, and cut in 3-lm thick slides. The 3-lm sections were deparaffined, hydrated, hematoxylin-eosin stained, and evaluated for histopathology. To identify connective tissue, samples were Masson-Goldner trichrome stained.
Immunohistochemistry
Antisera. The antiserum to NTS (NTSAS) was raised in rabbits using a glutaraldehyde-bovine thyroglobulin conjugate of the synthetic peptide (Peninsula Laboratories, Belmont, CA), which was kindly provided by Dr. G. Tramu (Laboratoire de Neurocytochimie Fonctionnelle, Talence, France); its immunological characteristics have been reported elsewhere [18] .
Two different NTSR1 receptor antisera were used. First, antiserum to NTS receptor 1 (NTSR1AS) raised in rabbits against the specific carboxy-terminal sequence 375-387 (NFRQVFLSTLACL), which was kindly provided by Dr. G. Tramu. The antibody was prepared by immunization of rabbits with this peptide coupled to glutaraldehyde-treated bovine serum albumin [19] . Second, antiserum N-18 was raised in goats against an epitope mapping near the Nterminus of human NTSR1 (Santa Cruz Biotechnology, Santa Cruz, CA).
Immunohistochemistry techniques. Deparaffined sections were rehydrated in TBS (0.05 M Tris and 0.05 M NaCl, pH 7.4), which was used for all further incubations and washes. The sections were incubated overnight at room temperature with NTSAS (1:500), NTSR1AS (1:300), and N-18 (1:100) in TBS containing 0.2% Triton X-100. After rinsing, the sections were incubated with a biotinylated goat anti-rabbit or rabbit anti-goat antibody (1:1000) followed by a streptavidin-peroxidase conjugate (1:1000; Jackson ImmunoResearch, West Grove, PA), both for 60 min at room temperature. Peroxidase activity was detected using 4-chloro-1-naphthol (Sigma Aldrich Co., Madrid, Spain) and 0.01% hydrogen peroxide. The specificity of the immunostaining was assessed by replacing the specific antisera by normal serum, omitting one step of the reaction or following preabsorption of the antisera with the corresponding antigens.
In order to demonstrate the coexistence of NTS and NTSR1 in leiomyoma cells, slides were treated as described above using antisera to NTS and then processed according to the elution-restaining procedure [20] using anti-NTSR1. The sites of peroxidase attachment in the second immunoreaction were demonstrated by incubation with 0.005% 3,3 0 -diaminobenzidine tetrahydrochloride (Sigma Aldrich Co.) in 0.05 M Tris-HCl, pH 7.6, containing 0.004% H 2 O 2 . To check the consistency of these results, the sequence of the antisera was inverted in some cases. In the second reaction performed after elution of the first antibody, the substitution of the specific antiserum by normal rabbit serum resulted in the complete absence of staining.
Quantitative analysis. Samples of leiomyomas were examined by light microscopy (Leitz Laborlux S, Leitz, Germany). The neurotensin-immunoreactive cells per unit area (1000 lm 2 ) were counted using Leica Q-Win software (Analysis Image System Leica Q-Win, Barcelona, Spain). Ten fields from the same section were measured, and two sections were analyzed per case. Only cell profiles with both immunostained cytoplasm and a nonstained nucleus were counted. Other stained fragments and artifacts were excluded by the program itself, which is set to a particular minimum size of object. The criterion used to consider a cell immunoreactive was the intensity of immunostaining, which was evaluated in arbitrary units of grey levels ranging from 1 (black) to 256 (white). Cells with values higher than those of the background of their control sections were considered to be reactive.
Statistical Analysis
SPSS version 11.0 was used. Differences between the groups were tested using ANOVA-test, and P values less than 0.05 were considered significant.
In Situ Hybridization
Probe. A synthetically produced 39-mer oligonucleotide probe complementary to NTS/neuromedin mRNA was used. The probe was labeled at the 3 0 end using terminal deoxynucleotidyl transferase. The reaction was carried out as follows: 1.5 mM CoCl 2 , 50 ng of probe, 2 nM of digoxygenin 11-ddUTP, and 50 units of terminal deoxynucleotidyl transferase (Roche, Basel, Switzerland) were added to a tailing buffer (pH 6.5) consisting of 200 nM sodium cacodylate, 200 nM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 4 mM 2-mercaptoethanol, and 50% glycerol (v/v). The volume was completed to 20 ll with sterile water, and the mixture was incubated at 378C for 1 h. For probe precipitation, 1 ll of yeast tRNA (10 mg/ml) was added, and the volume was brought to 90 ll with sterile water. Then, 10 ll of 3 M potassium acetate (pH 4.5) and absolute ethanol were added, and the mixture was left at À808C for 1 h. After centrifugation (13 000 rpm) at 48C for 30 min, the supernatant was discarded and the pellet resuspended in Tris-EDTA (10:1). The following controls were performed, none of which produced any detectable signal: (a) no probe; (b) with an excess of unlabeled probe, and (c) pretreated with a solution of RNase A (10 mg/ml).
Hybridization and washes. The 3-lm sections were deparaffined, hydrated with 4X SSC (1X SSC: 0.15 M NaCl and 0.015 M sodium citrate; ph ¼ 7), and then permeabilized with 10 lg/ml RNase-free proteinase K (Sigma Aldrich Co., Madrid, Spain) for 30 min at 378C in prehybridization buffer (3% Denhart's plus 0.5% sarcosyl in 4X SSC). After being washed in 4X SSC, the sections were dehydrated three times in ethanol and then allowed to dry at room temperature. Each section was overlaid with 100 ll of hybridization buffer (50% deionized formamide, 2X SSC, 10% dextran sulfate, 5% sarcosyl, and 25 lg/ml of salmon sperm DNA) containing 10 ng of digoxygenin-labeled oligonucleotide probe, covered with a glass coverslip, and incubated in a humidity chamber at 428C overnight. Following hybridization, the coverslip was removed by immersing the slide in 4X SSC, and the sections were washed in the same buffer. The following posthybridization washes were performed: two changes of 1X SSC for 15 and 45 min at room temperature, two changes of 1X SSC for 15 and 45 min at 428C, and two changes of 0.1X SSC for 15 and 45 min at 428C.
Probe detection. The sections were washed with STMT buffer (1 M NaCl, 0.1 M Tris, 0.005 M MgCl 2 , and 0.05% Tween 20, pH 7.5) for 1 h and then incubated for 30 min with an alkaline phosphatase-conjugated anti-digoxygenin antibody (Roche, Basel, Switzerland) at a 1:100 dilution in STMT buffer at room temperature. Alkaline phosphatase activity was revealed using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as substrate in STM buffer (0.1 M NaCl, 0.1 M Tris, and 0.005 M MgCl 2 , pH 9.5).
In order to demonstrate the presence of NTSR1 in the cells expressing NTS mRNA, a double in situ hybridization-immunohistochemical procedure was carried out. The slides were treated as described above using a probe for NTS/ neuromedin mRNA and then processed according to the immunohistochemical procedure using anti-NTSR1. 
RNA Extraction
NTSR1 mRNA was analyzed in 12 paired samples of leiomyomas and adjacent myometrial tissue. To avoid degradation, tissue sections were immersed in RNAlater (Sigma Aldrich Co.) immediately after surgery, kept at 48C overnight, and stored at À208C until RNA extraction. Then, 20 mg of tissue was homogenized using Lysing Matrix A tubes (MP Biomedicals, Illkirch, France) containing 1 ml of RA1 lysis buffer (GeHealthcare BioSciences AB, Uppsala, Sweden) in a FastPrep apparatus (MP Biomedicals). Subsequent RNA purification was performed using the Illustra RNAspin Mini Kit (GeHealthcare Bio-Sciences AB) according to the manufacturer's instructions.
RT-PCR
Residual genomic DNA was removed by incubating the RNA samples with RNase-free DNaseI and RNasin (Promega, Madison, WI). The effectiveness of the DNase treatment was assessed in RT-negative samples. First strand cDNA was synthesized from 2 lg of RNA using Moloney murine leukemia virus reverse transcriptase, RNase H Minus, Point Mutant (Promega) and random hexamers according to the manufacturer's instructions (Promega). To detect NTSR1 and the possible alternative splice variants, we used the same primers combination as previously described [17] .
PCR mixes contained 0.2 lM primers, 0.2 ll Phire Hot Start DNA polymerase (Finnzymes, Espoo, Finland), 1.5 mM MgCl 2 , 200 lM dNTPs, and 1/10 dilution of cDNA in a final volume of 20 ll. The PCR reactions included an initial 988C denaturation step for 30 sec, and then 35 cycles under the following conditions: 10 sec at 988C, 10 sec at 608C, and 15 sec at 728C. The beta isoform of the protein phosphatase-1 housekeeping gene, PPP1CB, served as the control for the RT-PCR reactions with 25 rounds of amplification.
Detection and Sequence Analysis of the PCR Products
Five microliters of the PCR products was electrophoresed in 1.7% agarose gels in Tris-borate EDTA buffer (0.089 M Tris, 0.089 M boric acid, and 0.002 M EDTA) and detected by ethidium bromide staining. Amplicon sizes were verified by comparison with a DNA mass ladder, and the identity of each PCR product was established by DNA sequence analysis in our university facilities using the DYEnamic ET Dye Terminator Cycle Sequencing Kit (GeHealthcare Bio-Sciences AB, Uppsala, Sweden). The sequencing reactions were run in a MegaBACE 1000 DNA Analysis System (GeHealthcare Bio-Sciences AB).
Electropherograms were visualized with the software Chromas (Technelysium Pty. Ltd., Tewantin, Australia).
RESULTS
NTS Expression in Myometrial and Leiomyoma Tissue
Neurotensin immunoreactive (NTS-ir) cells were observed only in connective tissue cells of normal myometrium (Fig. 1a) . In leiomyoma tissue, in addition to the connective cells, a variable number of smooth muscle cells were NTS-ir (Fig. 1b) . The mean number of NTS-ir smooth muscle cells was 14.4%, which was independent of tumor location. Interestingly, leiomyomas obtained from patients after hormonal treatment for IVF showed a statistically significant increase (P ¼ 0.015) in NTS-ir smooth muscle cells (Fig. 1, c and d ). This two-fold increase (33.8%) in NTS-ir tumoral cells was similar in all the patients analyzed.
In situ hybridization confirmed the expression of NTS mRNA in both normal connective cells and smooth muscle tumoral cells (Fig. 2, a and b) .
NTSR1 Expression in Myometrial and Leiomyoma Tissue
NTSR1 immnunoreactive (NTSR1-ir) connective tissue cells were present in normal myometrium (Fig. 3a) , while only a few smooth muscle cells showed some weak staining (Fig. 3a) . However, when leiomyomas were compared with the adjacent myometrium, a marked increase was clearly observed in the NTSR1-ir smooth muscle cells of every leiomyoma that was analyzed (Fig. 3b) . The NTSR1 immunoreaction of smooth muscle cells varied among the patients, but no correlation was found with tumor location. As was found with NTS immunoreactivity, the smooth muscle cells of leiomyomas from patients receiving hormonal treatment showed increased NTSR1 immunoreactivity (Fig. 3c) .
Analysis of NTSR1 by RT-PCR detected expression of the full-length transcript only in leiomyomas from 4 patients (33%) 
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but not in the matched normal myometrium (Fig. 4a) . Interestingly, we also detected two alternative splice variants: NTSR1_v1 and NTSR1_v2 previously described, respectively, as NTSR1a and NTS1Rb [16] . NTSR1_v1 was detected in tumoral tissue of 3 patients (25%) expressing native NTSR1 receptor but not in the adjacent normal myometrium (Fig. 4b) . Two of these patients also present the NTSR1_v2 isoform (Fig.  4c) .
NTSR1-NTS Coexpression in Leiomyoma Cells
The elution-restaining procedure revealed that most of the smooth muscle cells from NTS-ir leiomyomas were also NTSR1-ir (Fig. 5, a and a' ). In addition, the double staining process showed that most of the smooth muscle cells that stained positively for NTS mRNA were also NTSR1-ir (Fig. 5,  b and b' ). On the other hand, cells from connective tissue were NTS-ir or NTSR1-ir but only a very few showed immunoreactivity for both NTS and NTSR1 (Fig. 5, c and c' ).
DISCUSSION
In this study, we analyzed the expression at the cellular and molecular level of the peptide neurotensin and its high-affinity receptor, NTSR1, in leiomyomas and compared these data with adjacent myometrial tissue. Furthermore, we included leiomyomas from patients who had received hormonal treatment for IVF. Our main findings are: 1) NTS and NTSR1 immunore- activity is detected in connective tissue in normal myometrium; 2) in addition to connective tissue cells, NTS and NTSR1 immunoreactivity are observed in smooth muscle cells only from leiomyomatous tissue where immunoreactivity for both antibodies are colocalized in the same cell; 3) leiomyoma smooth muscle cells express NTS, as indicated by detection of NTS mRNA by in situ hybridization; 4) hormonal treatment significantly increases the NTS and NTSR1 immunoreactivity in leiomyoma smooth muscle cells; and 5) the new isoforms of NTSR1 are detected only in leiomyomas.
Neurotensin in peripheral organs is an endocrine hormone of the digestive tract [9] , a paracrine or autocrine modulator of the nervous and neuroendocrine systems as well as a growth factor in different normal cells, such as small bowel, colon, pancreas, and adrenal cortex [7] . We have analyzed for the first time the expression of NTS and its high affinity receptor NTSR1 in myometrium and leiomyoma. We detected NTS-ir and NTSR1-ir cells in connective tissue from myometrium. In addition, in situ hybridization demonstrated that connective cells express NTS mRNA. However, RT-PCR did not amplify the NTSR1 transcript in any of the myometria analyzed. Experiments performed on different cell systems demonstrated that NTS exerts a posttranscriptional regulation of NTSR1 expression by destabilizing NTSR1 mRNA [21] . This effect was observed after prolonged cell exposure and even at low doses of NTS. In addition, chronic in vivo administration of an NTSR1 antagonist resulted in an increase of NTSR1 mRNA in various brain regions and in the colon, indicating that, in vivo, NTS exerts a chronic negative regulation on NTSR1 expression. Similarly, it is feasible that NTS also acts in this way in 
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myometrium, limiting the number of de novo synthesized receptors. In connective tissue, paracrine signaling of growth factors between different cell types is observed to contribute to tissue homeostasis for normal organ functioning and tissue morphology [22] . Similarly, the presence of NTS and NTSR1 receptor in myometrial connective tissue suggests a paracrine mechanism of NTS signaling, which may be involved in the preservation of uterine functioning. In addition, some smooth muscle cells from myometrium show weak NTSR1 staining, suggesting that in normal physiological conditions, NTS released from connective cells may also act paracrinally on smooth muscle cells. It remains to be elucidated if any endocrine function is attributable to NTS release from myometrial connective cells.
Interestingly, the greatest differences when leiomyoma and myometrium were compared are seen in smooth muscle cells: leiomyoma shows both NTS-ir and increased NTSR1-ir cells, while absent or weak staining is observed in myometrium. In addition, a clear colocalization of NTSR1 receptor and NTS was detected in smooth muscle cells. Moreover, we observed that NTS is synthesized endogenously by smooth muscle cells because NTS mRNA was detected by in situ hybridization. This strongly supports a role for NTS as an autocrine growth factor in leiomyoma smooth muscle cells.
The majority of women receiving hormonal treatment for IVF suffered leiomyoma growth and an increased number of NTS-ir and NTSR1-ir smooth muscle cells. It is widely accepted that steroid hormones are involved in the growth of uterine leiomyomas [1] that in turn can induce secretion of growth factor peptides and the expression of their receptors [4] . In fact, estradiol induces NTS expression in neuroendocrine tissues [19, 23] and enhances NTS transcription in human breast epithelial cells [5] . The positive correlation of women receiving high doses of steroids with tumor growth and NTS-ir/ NTSR1-ir cell increase is in agreement with these previous studies and supports a role for sexual steroids in inducing NTS in leiomyomatous tissue, which in turn can act as a growth factor in this tumor.
Regarding NTSR1 expression, 4 out of 12 leiomyomas (33%) expressed NTSR1 mRNA as indicated by RT-PCR. This is an interesting point because it has been previously observed that NTS only induces NTSR1 gene activation at high doses and prolonged agonist exposure [21] . Under these conditions, NTSR1 is accumulated in the perinuclear recycling compartment and then recycled back to the plasma membrane. De novo receptor synthesis and continuous receptor recycling leads to permanent cell sensitivity to NTS, which would enhance tissue survival and proliferation [21] . This situation is found in colon adenoma, another benign tumor where NTSR1 shows a perinuclear localization suggesting intensive NTS stimulation [24] . Similarly NTS was also abnormally highly expressed in pancreatic tumors [25] , while in prostate cancer, NTS acts as autocrine trophic factor stimulated by androgen withdrawal [10] . In addition, NTSR1 is abnormally overexpressed in ovarian, pancreatic, and prostate cancers, Ewing's sarcomas, meningiomas, and astrocytomas [8, 9, 26, 27] . In agreement with these previous studies, we found that in leiomyomas the NTS continuously synthesized from smooth muscle cells can contribute to increasing the level of NTS stimulating the transcription of the NTSR1 gene. This abnormal autocrine regulation leads to permanent cell sensitivity to NTS, promoting smooth muscle cell proliferation. Therefore, the correct doses of NTS are crucial to limit the number of NTSR1 receptors on the cell surface, and the highest levels of NTS may occur in the four leiomyomas expressing NTSR1 mRNA. However, it should be noted that leiomyomas are benign tumors that rarely undergo malignant transformation. Therefore, the common mechanism among all these tumor types is that the NTS pathway could be activated at an early stage of tumorigenesis. In other tumors, later stages lead to malignant transformation but not in most leiomyomas where cells continue to proliferate, resulting in the symptoms normally associated with them: pelvic pain, profuse menstrual bleeding, or reproductive dysfunction. This is in agreement with a study conducted in colon cancer [15] , where NTSR1 expression increases gradually from low in normal tissue and moderate in adenoma to high in adenocarcinoma. In addition, in the present study we found that NTSR1 is barely detected in smooth muscle cells of myometrium but increases in leiomyomas along with de novo NTS synthesis; in addition, both NTS and NTSR1 are also expressed in uterine leiomyosarcoma (unpublished data).
Finally, three of the leiomyomas expressing NTSR1 mRNA also present new alternative splice variants of NTSR1, one tumor expressing only NTSR1_v1 and two expressing NTSR1_v1 and NTSR1_v2 [17] . These mRNA would encode two truncated forms of 336 amino acids and 280 aminoacids, respectively, which coexist with the native protein (418 aminoacids). Functional studies performed on truncated isoforms of G protein-coupled receptor structurally similar to those described here found that they are able to bind agonists, can couple to intracellular signaling pathways, and can associate both with themselves and with the native receptor to form homo-and heterodimer species, respectively [17] . We are currently conducting experiments to determine the function of the different NTSR1 isoforms.
In conclusion, our findings suggest steroid hormones induce neurotensin expression in smooth muscle cell leiomyoma. In these cells, NTS would act autocrinally through NTSR1 receptor promoting their proliferation. Once it is established that the NTS/NTSR1 pathway promotes leiomyoma proliferation, the use of drugs aimed to alter NTS receptor expression and function could block this autocrine pathway, reducing or suppressing tumor proliferation. Alternatively, the alternative splicing of NTSR1 could be a potential selective target in treating uterine tumors, as has been proposed for cancer-related transmembrane proteins [28] .
